• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Study on the expression of various mediators and CINV during moderately emetogenic risk chemotherapy.

Research Project

Project/Area Number 17K09312
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field General internal medicine(including psychosomatic medicine)
Research InstitutionSapporo Medical University

Principal Investigator

Okita Kenji  札幌医科大学, 医学部, 助教 (70517911)

Co-Investigator(Kenkyū-buntansha) 植木 知身  札幌医科大学, 医学部, 助教 (00516627)
九冨 五郎  札幌医科大学, 医学部, 講師 (10404625)
竹政 伊知朗  札幌医科大学, 医学部, 教授 (50379252)
西舘 敏彦  札幌医科大学, 医学部, 助教 (80404606)
Project Period (FY) 2017-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
KeywordsCINV / NK1RA / MEC / 化学療法 / 悪心 / 嘔吐 / 中等度催吐性リスク / NK1受容体拮抗薬 / 5-HT3受容体拮抗薬
Outline of Final Research Achievements

As the Clinical Research Act came into force during the study period, the study had to be applied for as a specific clinical study in order to carry out the study as originally planned, but application was difficult and the study plan had to be changed. In addition, the study was temporarily suspended due to the COVID-19 pandemic during the study period, and changes in the chemotherapy regimen being carried out at the department meant that blood data could only be obtained for 10 patients, and the original aim could not be completed. However, the results of the CINV study were used for a conference presentation on individualised treatment. They also assisted the then ongoing research on steroid reduction for moderate emetogenic risk.

Academic Significance and Societal Importance of the Research Achievements

現在、中等度催吐性リスク抗がん薬におけるCINV予防に関するトピックとしては、オランザピンの適応の必要性や、超遅発期CINVの実態把握やそれに対する予防療法の確立である。本研究は予定した研究を完遂できず目的は達成できなかったが、CINVに対する個別予防を研究するという研究ストラテジーは、上記の現在における制吐療法の問題点においても適応可能であると考えられる。

Report

(7 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (3 results)

All 2021 2019 2017

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results) Presentation (1 results)

  • [Journal Article] Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis2021

    • Author(s)
      Aogi K, Okita K, et al.
    • Journal Title

      Int J Clin Oncol .

      Volume: 26 Issue: 1 Pages: 1-17

    • DOI

      10.1007/s10147-020-01818-3

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.2019

    • Author(s)
      Okada Y, Okita K, et al
    • Journal Title

      Oncologist

      Volume: 24 Pages: 1593-1600

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] 患者催吐因子を考慮した制吐療法提案の試み2017

    • Author(s)
      益子寛之、沖田憲司 、高田 遼、山崎将英、國本雄介、木明智子、中田浩雅、野田師正、竹政伊知朗、宮本 篤
    • Organizer
      日本サポーティブケア学会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi